Nicox Ophthalmics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2007-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.nicox.com
Clinical Trials
7
Active:0
Completed:7
Trial Phases
2 Phases
Phase 2:4
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 3
3 (42.9%)Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05938699
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT04675242
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: NCX 470 0.1%
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 696
- Registration Number
- NCT04630808
- Locations
- 🇨🇳
Nicox Clinical Site, Tianjing, China
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: NCX 470 0.1% (initial phase of trial)Drug: NCX 470 0.1% (remainder of trial)Drug: NCX 470 0.065% (initial phase of trial)
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 691
- Registration Number
- NCT04445519
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nicox Ophthalmics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03926026
- Locations
- 🇺🇸
Texan Eye, Austin, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found